Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Neutral

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Neutral

B

Castle Biosciences, Inc. Common Stock (CSTL)

Services-medical Laboratories

https://www.castlebiosciences.com

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

505 S FRIENDSWOOD DRIVE, SUITE 401
FRIENDSWOOD, TX

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/25/2019

Market Cap

744,733,080

Shares Outstanding

26,910,000

Weighted SO

26,910,548

Total Employees

N/A

Upcoming Earnings

08/05/2024

Similar Tickers

CDNA --.--%

TWST --.--%

BDSX --.--%

NTRA --.--%

GTH --.--%

OLK --.--%

FONR --.--%

XGN --.--%

PSNL --.--%

Beta

0.9260

Last Div

0.0000

Range

12.07-28.22

Chg

-0.2900

Avg Vol

380720

Mkt Cap

744733080

Exch

NASDAQ

Country

US

Phone

866 788 9007

DCF Diff

7.8757

DCF

33.8757

Div Yield

0.0000

P/S

2.5896

EV Multiple

6983.2557

P/FV

1.7511

Div Yield %

0.0000

P/E

-239.5273

PEG

-5.4128

Payout

0.0000

Current Ratio

8.1210

Quick Ratio

7.9179

Cash Ratio

2.1689

DSO

58.3667

DIO

48.5661

Op Cycle

106.9328

DPO

57.8211

CCC

49.1117

Gross Margin

0.7906

Op Margin

-0.0548

Pretax Margin

-0.0140

Net Margin

-0.0108

Eff Tax Rate

0.2285

ROA

-0.0064

ROE

-0.0077

ROCE

-0.0352

NI/EBT

0.7715

EBT/EBIT

0.2549

EBIT/Rev

-0.0548

Debt Ratio

0.0231

D/E

0.0265

LT Debt/Cap

0.0231

Total Debt/Cap

0.0258

Int Coverage

62.5278

CF/Debt

4.1172

Equity Multi

1.1496

Rec Turnover

6.2536

Pay Turnover

6.3126

Inv Turnover

7.5155

FA Turnover

5.7221

Asset Turnover

0.5902

OCF/Share

1.6730

FCF/Share

0.9269

Cash/Share

9.3933

OCF/Sales

0.1608

FCF/OCF

0.5540

CF Coverage

4.1172

ST Coverage

37.7268

CapEx Coverage

2.2421

Div&CapEx Cov

2.2421

P/BV

1.7511

P/B

1.7511

P/S

2.5896

P/E

-239.5273

P/FCF

29.0639

P/OCF

16.0486

P/CF

16.0486

PEG

-5.4128

P/S

2.5896

EV Multiple

6983.2557

P/FV

1.7511

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Apr 30, 21:00 New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity MarketWatch Dec 28, 07:46 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky MarketWatch Dec 28, 06:34 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky Zacks Investment Research Nov 02, 19:30 Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q3 Earnings Zacks Investment Research Nov 02, 19:30 Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q3 Earnings

Revenue Product Segmentation